1,101 results on '"Wojdyla, Daniel"'
Search Results
52. LB-1 | Temporal Trends and Clinical Outcomes with Radial Versus Femoral Arterial Access for Percutaneous Coronary Intervention in the United States
53. Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery
54. Digoxin and Mortality in Patients With Atrial Fibrillation
55. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial
56. Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Nonranked Hospitals in the United States
57. Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial
58. Novel application of approaches to predicting medication adherence using medical claims data
59. Apixaban versus Warfarin in Patients with Atrial Fibrillation and Advanced Chronic Kidney Disease
60. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial
61. Abstract 15664: Prior Oral Anticoagulant Status and Outcomes in Patients With Atrial Fibrillation With an Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the Augustus Trial
62. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy
63. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial
64. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS
65. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial
66. Trends in Usage and Clinical Outcomes of Coronary Atherectomy: A Report From the National Cardiovascular Data Registry CathPCI Registry
67. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial
68. Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
69. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial
70. Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and Extremes in Body Weight: Insights from the ARISTOTLE Trial
71. WOMEN IN EXPLORER-HCM HAD MORE SEVERE HEART FAILURE AT BASELINE BUT SIMILAR, OR GREATER, RESPONSE TO MAVACAMTEN
72. THE EFFECT OF MAVACAMTEN TREATMENT FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS OF OLDER AGE AND LONGER DURATION OF DIAGNOSIS: ANALYSIS OF THE EXPLORER-HCM TRIAL
73. THE EFFECT OF MAVACAMTEN TREATMENT FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS WITH OR WITHOUT HYPERTENSION: ANALYSIS OF THE EXPLORER-HCM TRIAL
74. OBSTRUCTIVE HCM PATIENTS IN EXPLORER-HCM WITH HIGH LEFT VENTRICULAR FILLING PRESSURES HAD MORE SEVERE HEART FAILURE BUT SIMILAR OR GREATER RESPONSE TO MAVACAMTEN
75. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial
76. Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women
77. Quantifying Importance of Major Risk Factors for Coronary Heart Disease
78. Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention: Report From the NCDR CathPCI Registry
79. Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification
80. Predictive Accuracy of Stroke Risk Prediction Models Across Black and White Race, Sex, and Age Groups
81. Distribution of postpartum blood loss: modeling, estimation and application to clinical trials
82. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
83. Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect
84. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures
85. Central venous pressure after coronary artery bypass surgery: Does it predict postoperative mortality or renal failure?
86. TCT-347 Operator-Level Use of Intravascular Lithotripsy Across the USAs: Insights From the CathPCI Registry.
87. Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
88. TCT-20 Relative Benefit of Double Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Randomized Earlier Versus Later After Index Coronary Event: Insights From the AUGUSTUS Trial
89. TCT-586 Outcomes and Institutional Variation in Arterial Access Choice Among Patients With Acute Myocardial Infarction and Cardiogenic Shock Undergoing PCI: An Analysis From the CathPCI Registry
90. TCT-1 Bleeding in Patients With Atrial Fibrillation and Acute Coronary Syndrome or PCI Treated With Antithrombotic Therapy: Insights From the AUGUSTUS Trial
91. Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)
92. Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults
93. Characteristics and Outcomes of Patients With Heart Failure and Discordant Findings by Right-Sided Heart Catheterization and Cardiopulmonary Exercise Testing
94. Comparison of Safety of Sotalol Versus Amiodarone in Patients With Atrial Fibrillation and Coronary Artery Disease
95. Blood Pressure Response during Cardiopulmonary Exercise Testing in Heart Failure
96. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial
97. Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry
98. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)
99. Abstract 18003: Patients With Good Adherence to Study Medication Have Better Outcomes: Insights From the ARISTOTLE Trial
100. Abstract 16493: Variation in Patient Characteristics Does Not Explain Regional Differences in Outcomes: Findings From ARISTOTLE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.